Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose PK/PD study of TSP-101 in healthy Japanese male adults
jRCT2071260012Phase 1Completed
- Sponsor
- Tensegrity Pharma
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSP-101 (3 arms), sponsored by Tensegrity Pharma. Primary endpoints: Pharmacokinetic parameters of plasma TSP-101 and Plasma concentration of total sFn14 and free sFn14. Started May 2026; status: completed.
02
Drugs
TSP-101
Beyond the preview
Go deeper on jRCT2071260012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260012.